---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116712"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:06:52.189858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201

## Summary
- $88.2M private placement closed Nov 1; cash runway extended through end of 2025.
- Phase 1b: VYN201 mean F-VASI reduction 30.2% (1%) and 39.0% (2%) at 16 weeks; well-tolerated.
- Phase 2b trial for VYN201 in vitiligo expected H1 2024; top-line results mid-2025.
- VYN202 IND submission by year-end 2023; Phase 1a trial in Q1 2024; Phase 1b in psoriasis/RA H2 2024.
- Q3 2023 GAAP net loss $6.6M, adjusted net loss $5.7M; cash runway through 2025.

## SEC filing metadata
- accession: 0001104659-23-116712
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/0001104659-23-116712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/tm2330394d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116712
- JSON: https://secwatch.observer/filing/0001104659-23-116712.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116712.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2023.
  - Period: the three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/0001104659-23-116712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.